Home › Research › Clinical trials
Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer's disease
Wischik CM, Stefanacci R, Bentham P, Gauthier S, Zetterberg H, Wilcock GK, Froelich L, Burns A, MacSweeney E, Ballard C, et al.. The Journal of Prevention of Alzheimer's Disease, 2026-01-21
Topic: Brain proteins, microglia and lab models
Plain-language summary
Intervention HMTM 16 mg/day and 8 mg/day were compared with methylthioninium chloride (MTC) 4 mg twice weekly, intended as an inactive urinary colourant to preserve blinding with respect to possible urinary discolouration caused by HMTM. Results It was not possible to demonstrate significant differences on the co-primary clinical endpoints (ADAS-cog 11 and ADCS-ADL 23 ) at 52 weeks due to symptomatic activity in the control arm. In participants with MCI, statistically significant differences in cognitive decline (ADAS-cog 13 ) emerged at 78 weeks (p = 0·0291) and 104 weeks (p = 0·0308) between early- and delayed-start HMTM 16 mg/day in analyses specified prior to the 24-month database lock. Statistically significant cognitive improvement over baseline score was sustained for 78 weeks in the early start MCI group, with no significant cognitive or functional decline to 104 weeks. There was a significant reduction in progression of neurodegeneration measured by NfL change (p = 0·0291) at 52 weeks in the whole population, consistent with significant reductions in progression of grey matter atrophy at 52 and 104 weeks, and a reduction in progression of tau pathology (pTau217, p = 0·0165) in MCI. In participants with MCI, significant clinical separation was seen only at 78 and 104 weeks.
What this study adds
Evidence grade: Null result
The record lists 598 participants. This Phase 3 trial could not show significant differences on its main clinical endpoints at 52 weeks because the control arm also showed symptomatic activity. Its stated limit: Failed primary endpoints; comparator was a low dose of the same compound rather than true placebo; positive results are subgroup and secondary analyses; sponsored and authored by the developer.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Wischik, C. M., Stefanacci, R., Bentham, P., Gauthier, S., Zetterberg, H., Wilcock, G. K., et al. (2026). Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer's disease. The Journal of Prevention of Alzheimer's Disease. https://doi.org/10.1016/j.tjpad.2026.100480
Vancouver
Wischik CM, Stefanacci R, Bentham P, Gauthier S, Zetterberg H, Wilcock GK, et al. Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer's disease. The Journal of Prevention of Alzheimer's Disease. 2026. doi:10.1016/j.tjpad.2026.100480. PMID: 41570392.
BibTeX
@article{wischik2026-41570392,
author = {Wischik, C. M. and Stefanacci, R. and Bentham, P. and Gauthier, S. and Zetterberg, H. and Wilcock, G. K. and Froelich, L. and Burns, A. and MacSweeney, E. and Ballard, C. and others},
title = {{Clinical, imaging and blood biomarker outcomes in a Phase 3 clinical trial of tau aggregation inhibitor hydromethylthionine mesylate in mild cognitive impairment and mild to moderate dementia due to Alzheimer's disease}},
journal = {The Journal of Prevention of Alzheimer's Disease},
year = {2026},
doi = {10.1016/j.tjpad.2026.100480},
pmid = {41570392},
url = {https://doi.org/10.1016/j.tjpad.2026.100480}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Intervention HMTM 16 mg/day and 8 mg/day were compared with methylthioninium chloride (MTC) 4 mg twice weekly, intended as an inactive urinary colourant to preserve blinding with respect to possible urinary discolouration caused by HMTM.
- Results It was not possible to demonstrate significant differences on the co-primary clinical endpoints (ADAS-cog 11 and ADCS-ADL 23 ) at 52 weeks due to symptomatic activity in the control arm.
- In participants with MCI, statistically significant differences in cognitive decline (ADAS-cog 13 ) emerged at 78 weeks (p = 0·0291) and 104 weeks (p = 0·0308) between early- and delayed-start HMTM 16 mg/day in analyses specified prior to the 24-month database lock.
- Statistically significant cognitive improvement over baseline score was sustained for 78 weeks in the early start MCI group, with no significant cognitive or functional decline to 104 weeks.
- There was a significant reduction in progression of neurodegeneration measured by NfL change (p = 0·0291) at 52 weeks in the whole population, consistent with significant reductions in progression of grey matter atrophy at 52 and 104 weeks, and a reduction in progression of tau pathology (pTau217, p = 0·0165) in MCI.
Why it matters
This Phase 3 trial could not show significant differences on its main clinical endpoints at 52 weeks because the control arm also showed symptomatic activity. In participants with mild cognitive impairment, some cognitive differences emerged at 78 and 104 weeks, and there were reductions in markers of neurodegeneration and tau pathology.
New to this subject? Start with our plain-English guide: Registered clinical trials →
Study details
- Study designphase-3-trial
- Participants598
- Evidence strengthNull-result
Limitations
Failed primary endpoints; comparator was a low dose of the same compound rather than true placebo; positive results are subgroup and secondary analyses; sponsored and authored by the developer.
How this study scored 60/100
Published in a peer-reviewed journal, and it is a large phase 3 trial. Scored zero for effect reported and randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 59 of the 98 points we could judge it on, which is 60 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The Journal of Prevention of Alzheimer's Disease) |
| Journal's citation record | 0 / 4 | The Journal of Prevention of Alzheimer s Disease: journal h-index 63 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A large phase 3 trial |
| Strength of evidence | 3 / 5 | Rated “null-result” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 2 / 4 | 598 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 9 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 4.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 5 / 6 | Cited 37.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 9 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Bjoern O. Schelter: h-index 15 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Oxford: institution h-index 2,205 (OpenAlex) |
| Multicenter collaboration | 3 / 3 | OpenAlex lists 21 institution(s) in 6 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41570392) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 59 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 59 of the 98 points we could judge it on is 60 out of 100. |
| Total | 60 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1016/j.tjpad.2026.100480
- PubMed: 41570392
- Original source →
- Free full text: PubMed Central →
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.
Related studies in Clinical trials from nearby years
Also tagged “phosphorylated”
732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.